Altogether, our data indicate AC-73 and SYRO as potential inhibitors of SARS-CoV-2 spike protein binding and entry, via CD147 and MCT4 respectively, into MKs co-expressing CD147 and MCT4, in contrast to ACE2 undetectable or very low expression in MKs derived from CD34+ HPCs, and precursors of platelets involved in the SARS-CoV-2 related coagulopathy in COVID-19 disease. Here, BSG is linked to blood coagulation disease.